{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:12:11Z","timestamp":1788455531850,"version":"build-2803163510"},"reference-count":47,"publisher":"MDPI AG","issue":"22","license":[{"start":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T00:00:00Z","timestamp":1637539200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Strategic Priority Research Program of the Chinese 631 Academy of Sciences","award":["XDB29030202"],"award-info":[{"award-number":["XDB29030202"]}]},{"name":"Ministry of Science and Tech- 632 nology of China","award":["2016YFC1303503"],"award-info":[{"award-number":["2016YFC1303503"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Natural killer (NK) cells have shown great therapeutic potential against a wide range of cancers due to their pan-specific target recognition. Numerous reports indicate that NK cell immunotherapy is an effective therapeutic approach for treating hematological malignancies, but shows limited effects against solid tumors. In this study, several models of ovarian cancer (OC) were used to test the anti-cancer effects of NK cells derived from human peripheral blood mononuclear cells and expanded using a feeder cell-free expansion system (eNKs). The results show that eNKs exhibit potent inhibitory activity on tumor growth in different ovarian cancer xenograft mice (i.e., solid tumors, abdominal metastatic tumors, and ascites), importantly, in a dose-dependent manner. Moreover, adoptive transfer of eNKs resulted in significant reduction in ascites formation in OC peritoneal tumor models, and especially in reducing intraperitoneal ascites. We found that eNKs could migrate to the tumor site, retain their activity, and proliferate to maintain high cell counts in cutaneous xenograft mice. In addition, when increased the infusion with a high dose of 12 \u00d7 107 cells\/mouse, Graft-versus-host disease could be induced by eNK. These data show that eNK cell immunotherapy could be a promising treatment strategy for ovarian cancers, including solid tumors and ascites.<\/jats:p>","DOI":"10.3390\/cancers13225866","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T02:55:17Z","timestamp":1637636117000},"page":"5866","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Anti-Tumor Activity of Expanded PBMC-Derived NK Cells by Feeder-Free Protocol in Ovarian Cancer"],"prefix":"10.3390","volume":"13","author":[{"given":"Minhua","family":"Chen","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"},{"name":"Hefei National Laboratory for Physical Sciences at Microscale, CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei 230027, China"},{"name":"Institute of Immunology, University of Science and Technology of China, Hefei 230027, China"},{"name":"Engineering Technology Research Center of Biotechnology Drugs Anhui, University of Science and Technology of China, Hefei 230027, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutong","family":"Li","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"},{"name":"Hefei National Laboratory for Physical Sciences at Microscale, CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei 230027, China"},{"name":"Institute of Immunology, University of Science and Technology of China, Hefei 230027, China"},{"name":"Engineering Technology Research Center of Biotechnology Drugs Anhui, University of Science and Technology of China, Hefei 230027, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8250-7571","authenticated-orcid":false,"given":"Yu","family":"Wu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"},{"name":"Hefei National Laboratory for Physical Sciences at Microscale, CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei 230027, China"},{"name":"Institute of Immunology, University of Science and Technology of China, Hefei 230027, China"},{"name":"Engineering Technology Research Center of Biotechnology Drugs Anhui, University of Science and Technology of China, Hefei 230027, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Xie","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"},{"name":"Hefei National Laboratory for Physical Sciences at Microscale, CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei 230027, China"},{"name":"Institute of Immunology, University of Science and Technology of China, Hefei 230027, China"},{"name":"Engineering Technology Research Center of Biotechnology Drugs Anhui, University of Science and Technology of China, Hefei 230027, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"},{"name":"Hefei National Laboratory for Physical Sciences at Microscale, CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei 230027, China"},{"name":"Institute of Immunology, University of Science and Technology of China, Hefei 230027, China"},{"name":"Engineering Technology Research Center of Biotechnology Drugs Anhui, University of Science and Technology of China, Hefei 230027, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Yue","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"},{"name":"Hefei National Laboratory for Physical Sciences at Microscale, CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei 230027, China"},{"name":"Institute of Immunology, University of Science and Technology of China, Hefei 230027, China"},{"name":"Engineering Technology Research Center of Biotechnology Drugs Anhui, University of Science and Technology of China, Hefei 230027, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Lv","sequence":"additional","affiliation":[{"name":"Blood Transfusion Laboratory, Anhui Blood Center, Hefei 230031, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhigang","family":"Tian","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"},{"name":"Hefei National Laboratory for Physical Sciences at Microscale, CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei 230027, China"},{"name":"Institute of Immunology, University of Science and Technology of China, Hefei 230027, China"},{"name":"Engineering Technology Research Center of Biotechnology Drugs Anhui, University of Science and Technology of China, Hefei 230027, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Fang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"},{"name":"Hefei National Laboratory for Physical Sciences at Microscale, CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei 230027, China"},{"name":"Institute of Immunology, University of Science and Technology of China, Hefei 230027, China"},{"name":"Engineering Technology Research Center of Biotechnology Drugs Anhui, University of Science and Technology of China, Hefei 230027, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9102-6326","authenticated-orcid":false,"given":"Weihua","family":"Xiao","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230001, China"},{"name":"Hefei National Laboratory for Physical Sciences at Microscale, CAS Key Laboratory of Innate Immunity and Chronic Disease, School of Life Sciences, University of Science and Technology of China, Hefei 230027, China"},{"name":"Institute of Immunology, University of Science and Technology of China, Hefei 230027, China"},{"name":"Engineering Technology Research Center of Biotechnology Drugs Anhui, University of Science and Technology of China, Hefei 230027, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1126\/science.1198687","article-title":"Innate or Adaptive Immunity? The Example of Natural Killer Cells","volume":"331","author":"Vivier","year":"2011","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41577-018-0061-z","article-title":"Natural killer cells and other innate lymphoid cells in cancer","volume":"18","author":"Chiossone","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-019-0052-1","article-title":"NK cells for cancer immunotherapy","volume":"19","author":"Shimasaki","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3389\/fimmu.2019.01205","article-title":"Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities","volume":"10","author":"Hu","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.smim.2017.07.009","article-title":"NK cell-based immunotherapy for cancer","volume":"31","author":"Fang","year":"2017","journal-title":"Semin Immunol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.3389\/fimmu.2017.00631","article-title":"The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments","volume":"8","author":"Veluchamy","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Navin, I., Lam, M.T., and Parihar, R. (2020). Design and Implementation of NK Cell-Based Immunotherapy to Overcome the Solid Tumor Microenvironment. Cancers, 12.","DOI":"10.3390\/cancers12123871"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3389\/fimmu.2012.00395","article-title":"Natural killer cells in non-hematopoietic malignancies","volume":"3","author":"Desbois","year":"2012","journal-title":"Front. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/CJI.0000000000000059","article-title":"Ex Vivo-expanded Natural Killer Cells Demonstrate Robust Proliferation In Vivo in High-risk Relapsed Multiple Myeloma Patients","volume":"38","author":"Szmania","year":"2015","journal-title":"J. Immunother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00262-017-2100-1","article-title":"Haploidentical natural killer cells induce remissions in non-Hodgkin lymphoma patients with low levels of immune-suppressor cells","volume":"67","author":"Bachanova","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41423-019-0206-4","article-title":"Human NK cells: Surface receptors, inhibitory checkpoints, and translational applications","volume":"16","author":"Sivori","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/s43018-020-0068-9","article-title":"Resistance to natural killer cell immunosurveillance confers a selective advantage to polyclonal metastasis","volume":"1","author":"Lo","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"101209","DOI":"10.1016\/j.nantod.2021.101209","article-title":"Dual-functional super bispecific nano-antibodies derived from monoclonal antibodies potentiate the antitumor effect of innate immune cells","volume":"39","author":"Chen","year":"2021","journal-title":"Nano Today"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1158\/2326-6066.CIR-18-0144","article-title":"Expanded CD56superbrightCD16+ NK Cells from Ovarian Cancer Patients Are Cytotoxic against Autologous Tumor in a Patient-Derived Xenograft Murine Model","volume":"6","author":"Poznanski","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11864-018-0584-3","article-title":"Review of Immune Therapies Targeting Ovarian Cancer","volume":"19","author":"Fan","year":"2018","journal-title":"Curr. Treat. Opt. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1158\/1940-6207.CAPR-19-0184","article-title":"Reducing Ovarian Cancer Mortality through Early Detection: Approaches Using Circulating Biomarkers","volume":"13","author":"Trinidad","year":"2020","journal-title":"Cancer Prev. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e1320630","DOI":"10.1080\/2162402X.2017.1320630","article-title":"Umbilical cord blood CD34+ progenitor-derived NK cells efficiently kill ovarian cancer spheroids and intraperitoneal tumors in NOD\/SCID\/IL2Rgnull mice","volume":"6","author":"Cany","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12307-018-0215-3","article-title":"Ascites IL-10 Promotes Ovarian Cancer Cell Migration","volume":"11","author":"Lane","year":"2018","journal-title":"Cancer Microenviron."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fonc.2013.00256","article-title":"Getting to know ovarian cancer ascites: Opportunities for targeted therapy-based translational research","volume":"3","author":"Ahmed","year":"2013","journal-title":"Front. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00404-018-4952-9","article-title":"Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: A retrospective analysis of 191 women treated at Bayreuth Hospital, 2006\u20132015","volume":"299","author":"Krugmann","year":"2019","journal-title":"Arch. Gynecol. Obstet."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00262-017-2112-x","article-title":"Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic against autologous primary ovarian cancer cells","volume":"67","author":"Nham","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2017.10.022","article-title":"Pre-clinical evaluation of a themosensitive gel containing epothilone B and mTOR\/Hsp90 targeted agents in an ovarian tumor model","volume":"268","author":"Shin","year":"2017","journal-title":"J. Control. Release"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1038\/s41467-021-21497-6","article-title":"Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy","volume":"12","author":"Jiang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"34810","DOI":"10.18632\/oncotarget.26199","article-title":"Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients","volume":"9","author":"Maas","year":"2018","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.3389\/fimmu.2019.01782","article-title":"Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer","volume":"10","author":"Nersesian","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ygyno.2020.03.020","article-title":"Harnessing natural killer cells for the treatment of ovarian cancer","volume":"157","author":"Bekkers","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"ref_27","first-page":"1071","article-title":"Natural killer cells inhibit metastasis of ovarian carcinoma cells and show therapeutic effects in a murine model of ovarian cancer","volume":"16","author":"Sun","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jcyt.2013.05.022","article-title":"Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model","volume":"15","author":"Geller","year":"2013","journal-title":"Cytotherapy"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/stem.2230","article-title":"Induced Pluripotent Stem Cell-Derived Natural Killer Cells for Treatment of Ovarian Cancer","volume":"34","author":"Hermanson","year":"2016","journal-title":"Stem Cells"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1002\/ijc.32779","article-title":"Interleukin-33 activates and recruits natural killer cells to inhibit pulmonary metastatic cancer development","volume":"146","author":"Qi","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.intimp.2012.09.014","article-title":"Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells","volume":"14","author":"Deng","year":"2012","journal-title":"Int. Immunopharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Liem, N.T., Van Phong, N., Kien, N.T., Anh, B.V., Huyen, T.L., Thao, C.T., Tu, N.D., Hiep, D.T., Hoai Thu, D.T., and Nhung, H.T.M. (2019). Phase I Clinical Trial Using Autologous Ex Vivo Expanded NK Cells and Cytotoxic T Lymphocytes for Cancer Treatment in Vietnam. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133166"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fimmu.2018.00150","article-title":"An Uncoupling of Canonical Phenotypic Markers and Functional Potency of Ex Vivo-Expanded Natural Killer Cells","volume":"9","author":"Lieberman","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jcyt.2020.02.004","article-title":"Artificial feeder cells expressing ligands for killer cell immunoglobulin-like receptors and CD94\/NKG2A for expansion of functional primary natural killer cells with tolerance to self","volume":"22","author":"Michen","year":"2020","journal-title":"Cytotherapy"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cytogfr.2020.12.003","article-title":"Chemokine networks modulating natural killer cell trafficking to solid tumors","volume":"59","author":"Yao","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1476-4598-9-11","article-title":"MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells","volume":"9","author":"Gubbels","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.exphem.2007.06.007","article-title":"Factors affecting human T cell engraftment, trafficking, and associated xenogeneic graft-vs-host disease in NOD\/SCID beta2mnull mice","volume":"35","author":"Nervi","year":"2007","journal-title":"Exp. Hematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fonc.2019.00051","article-title":"Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors","volume":"9","author":"Nayyar","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-020-01014-w","article-title":"NK cell-based cancer immunotherapy: From basic biology to clinical development","volume":"14","author":"Liu","year":"2021","journal-title":"J. Hematol Oncol."},{"key":"ref_40","first-page":"202","article-title":"Therapeutic potential and challenges of natural killer cells in treatment of solid tumors","volume":"6","author":"Bjorklund","year":"2015","journal-title":"Front. Immunol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000325465","article-title":"Natural killer cells and solid tumors","volume":"3","author":"Stojanovic","year":"2011","journal-title":"J. Innate Immun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.3389\/fimmu.2019.03038","article-title":"Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors","volume":"10","author":"Melaiu","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Greppi, M., Tabellini, G., Patrizi, O., Candiani, S., Decensi, A., Parolini, S., Sivori, S., Pesce, S., Paleari, L., and Marcenaro, E. (2019). Strengthening the AntiTumor NK Cell Function for the Treatment of Ovarian Cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20040890"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41416-020-0875-x","article-title":"The untapped potential of ascites in ovarian cancer research and treatment","volume":"123","author":"Ford","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.jcyt.2016.12.005","article-title":"Cord blood natural killer cells expressing a dominant negative TGF-beta receptor: Implications for adoptive immunotherapy for glioblastoma","volume":"19","author":"Yvon","year":"2017","journal-title":"Cytotherapy"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood.2020007748","article-title":"Targeting a cytokine checkpoint enhances the fitness of armored cord blood CAR-NK cells","volume":"137","author":"Daher","year":"2021","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1038\/s41423-021-00686-9","article-title":"Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model","volume":"18","author":"Thangaraj","year":"2021","journal-title":"Cell. Mol. Immunol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/22\/5866\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:34:10Z","timestamp":1760168050000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/22\/5866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,22]]},"references-count":47,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2021,11]]}},"alternative-id":["cancers13225866"],"URL":"https:\/\/doi.org\/10.3390\/cancers13225866","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,22]]}}}